| CIRCIO HOLDING NK 0,60 |
| Norwegen |
| Gesundheit |
| NO0013033795 / A3EUN9 |
| TA50 (Frankfurt) |
| FRA:TA50, ETR:TA50, TA50:GR |
| - |
| https://www.circio.com/ |
|
Circio Holding ASA is a clinical-stage biotechnology company headquartered in Lysaker, Norway, specializing in the development of novel circular RNA (circRNA) therapeutics and immuno-oncology immunotherapies for treatment-resistant cancers and diffic..
>Volltext.. |
| 359.93 Mio. EUR |
| 360.14 Mio. EUR |
| - |
| -3.77 Mio. EUR |
| -3.93 Mio. EUR |
| -0.04 EUR |
| 0.72 Mio. EUR |
| 0.52 Mio. EUR |
| -3.92 Mio. EUR |
| 0.26 |
| - |
| -179.81% |
| - |
| - |
| - |
| - |
| CIRCIO |
| 01.09.26 |
|